MaaT Pharma Treats First U.S. Patient with MaaT013 for Acute GvHD at City of Hope
MaaT Pharma, a clinical-stage biotechnology company specializing in Microbiome Ecosystem Therapies™ (MET) to improve cancer patient survival, announced the first treatment in the United States of a patient with acute Graft-versus-Host Disease (aGvHD) under the FDA’s Single Patient Expanded Access…
MEDIPAL and JCR Pharmaceuticals Begin Phase I/II Trial of JR-446 for MPS IIIB in Japan
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced today the initiation of the Phase I/II clinical trial for JR-446 in Japan, with the first participant dosed. JR-446 is a proprietary α-N-acetylglucosaminidase designed to…
XPRIZE Healthspan Offers USD$10 Million Bonus to Accelerate FSHD Breakthroughs
SOLVE FSHD, a venture philanthropy organization focused on accelerating new therapies for facioscapulohumeral muscular dystrophy (FSHD), is inviting innovators from around the globe to compete for the USD$10 million FSHD Bonus Prize. This prize is part of the XPRIZE Healthspan…
Cencora Unveils Accelerate Pharmacy Solutions to Boost Hospital and Health System Support
Cencora, a global healthcare leader, has introduced Accelerate Pharmacy Solutions, a comprehensive suite of services aimed at helping hospital and health system customers streamline operations and improve financial performance. This new portfolio consolidates Cencora’s pharmacy and supply chain solutions, providing…
VSee Health and AbundaBox Launch AbundaLife™ to Revolutionize Family Health Record Management
VSee Health, Inc. (Nasdaq: VSEE), a leader in telehealth solutions known for its scalable technology and clinical expertise, has partnered with AbundaBox to launch AbundaLife™, an innovative health record management platform. AbundaLife addresses the challenge of fragmented medical records by…
BostonGene to Present Twelve Abstracts at 66th ASH Annual Meeting
BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced that 10 of its abstracts have been selected for poster presentations, and two will be featured for online publication at the 66th American Society of Hematology (ASH) Annual…
Vevo Therapeutics Partners with Parse Biosciences to Create 100 Million Cell Atlas for AI Drug Discovery
Parse Biosciences, a leader in accessible and scalable single-cell sequencing solutions, has announced the creation of the world’s largest single-cell dataset to date, comprising 100 million cells. This milestone was achieved in just one month using Parse Biosciences’ GigaLab platform,…
Veracyte’s Decipher Prostate Test Now Only Gene Expression Test in NCCN® Guidelines
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that its Decipher Prostate Genomic Classifier is now the only gene expression test included in version 1 of the 2025 NCCN® Clinical Practice Guidelines in Oncology (NCCN Guidelines®). It is…
QIAGEN Hits 1,000 Milestone for EZ2 Connect Sample Prep Instrument
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a major milestone, surpassing 1,000 placements of its EZ2 Connect automated sample preparation instrument, a key advancement in the EZ1 instrument line. Launched in 2021, the EZ2 Connect has quickly become…
Lyra Health Appoints Jennifer Schulz as CEO
Lyra Health, a leader in innovative Workforce Mental Health solutions for employers and health plans, is excited to announce that Jennifer Schulz will join the company as Chief Executive Officer and Board member, effective January 13, 2025. Schulz will succeed…
Exai Bio Appoints Karen E. Knudsen to Board of Directors
Exai Bio, a leading RNA- and AI-based liquid biopsy company, has announced the appointment of Karen E. Knudsen, MBA, PhD, to its board of directors. Knudsen, the former CEO of the American Cancer Society (ACS) and its affiliate, the American…
Foresight Diagnostics Launches SHORTEN-ctDNA Trial for DLBCL Treatment Duration
Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, has announced the launch of the SHORTEN-ctDNA clinical trial at Columbia University. The study aims to assess the use of Foresight CLARITY™ MRD detection for real-time treatment optimization…